ArticleFrontiers in psychiatry2025
Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03333668 (Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is associated with cognitive difficulties which improve with traditional stimulant and non-stimulant medications. However, there is limited evidence on the cognitive effects of the newer licensed stimulant lisdexamfetamine and non-stimulant guanfacine in children with ADHD. Therefore, we compared differential single-dose effects of lisdexamfetamine and guanfacine on cognitive performance in youth with ADHD. Methods: In a randomized, placebo-controlled, double-blind, cross-over design, 22 children with ADHD were tested in tasks of sustained attention, vigilance, motor and interference inhibition, and time discrimination after single doses of guanfacine extended release, lisdexamfetamine, and placebo, with weekly washout Results: Lisdexamfetamine significantly improved MRT and CV, while guanfacine worsened CV, compared with placebo and the other drug, with large effects. Although not reaching significance, there were moderate to large effects for lisdexamfetamine improving time discrimination and omission errors and for guanfacine to worsen omission errors in a sustained attention task relative to placebo and the other drug. Conclusion: These differential effects of lisdexamfetamine improving MRT and CV, while guanfacine worsening CV are clinically relevant, because they are the most replicated cognitive impairments in youth with ADHD. Findings suggest that guanfacine, unlike lisdexamfetamine, may not improve attention in children and adolescents with ADHD. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT03333668?term=NCT03333668&rank=1#study-plan, identifier NCT03333668.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.